Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolastin plus standard medical treatment versus standard medical treatment alone in hospitalized adults with COVID-19
2020-001953-36Phase 2Completed
- Sponsor
- Instituto Grifols
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alpha-1-proteinase inhibitor in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Instituto Grifols. Primary endpoint: Composite of death, ICU admission, or invasive mechanical ventilation dependence by Day 15. Started May 2020; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001953-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001953-36.